A Phase IIb/III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities.
Phase of Trial: Phase II/III
Latest Information Update: 20 Mar 2015
At a glance
- Drugs Taranabant (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2012 Company (Merck Sharp and Dohme) added to the associations field as reported by European Clinical Trials Database record.
- 21 Jun 2012 Trial phase changed from III to II/III and exclusion criteria amended as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History